AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03703089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.
Study NCT03703089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered by intravenous infusion over 30-40 minutes.
Study NCT05276921 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: Quadriceps and abdominal muscle ultrasonography
Study NCT00955396 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Tablets
Study NCT00561678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine)
Description: 0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
Study NCT00561678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
Study NCT03228004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glooko MeterSync
Description: The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
Study NCT03367312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xenon gas
Description: Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
Study NCT05340842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training group
Description: In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
Study NCT00955396 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/d,once-weekly,per oral.
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/㎡,once-weekly,subcutaneous injection
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3mg/㎡,once-weekly,subcutaneous injection
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg/d,once-weekly,per oral
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg/d,once-weekly,per oral
Study NCT02362165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 9mg/㎡,d1-4
Study NCT02489175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stomaplasty KoringTM
Description: In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
Study NCT02353091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Microphone Hearing Aids
Description: The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
Study NCT04028011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Novel Wearable device
Description: patient will wear novel wearable device overnight along with normal standard of care
Study NCT00364780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL647
Description: XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
Study NCT04007172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural therapy
Description: Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
Study NCT04007172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
Study NCT04561401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial Magnetic Stimulation (rTMS)
Description: rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
Study NCT04561401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Pain Rehabilitation Program (IPRP)
Description: The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
Study NCT04561401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Pain Rehabilitation Program (IPRP)
Description: The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
Study NCT04138407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated Tai Chi
Description: Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
Study NCT04138407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual rehabilitation exercise
Description: Regular rehabilitation exercise used in participating hospital
Study NCT00974714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Oral L-arginine 2 g twice a day for 14 weeks
Study NCT00974714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo 2 g twice a day for 14 weeks
Study NCT02201303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Powdered form for in-vitro administration to blood sample
Study NCT02201303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CXCL1
Description: Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
Study NCT02967367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone sleep tracker
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
Study NCT02967367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings sleep tracker
Description: During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
Study NCT02952833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sodium chloride solution.
Study NCT02301871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Gene's Health and Wellness
Description: The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
Study NCT02301871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
Study NCT02301871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching and Cervical non thrust manipulation
Description: conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
Study NCT02952833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study NCT01777776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
Study NCT02788890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling without LA
Description: The patient will undergo a supragingival scaling procedure without local anesthesia
Study NCT02788890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple restoration under LA
Description: The patient will undergo a simple dental restoration procedure under local anesthesia
Study NCT02788890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple exodontia under LA
Description: The patient will undergo a simple dental extraction procedure under local anesthesia
Study NCT01481064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted approach
Description: Audit and feedback, educational outreach visits, and patient-mediated interventions.
Study NCT04416009 — intervention group
Intervention type: DEVICE
Intervention: NİCaS
Description: whole body bioimpedence method
Study NCT05599373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
Study NCT05599373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Active Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
Study NCT05599373 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS over bilateral dorsolateral prefrontal cortex
Description: Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: oral capsule
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Control Placebo
Description: oral capsule
Study NCT01777776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Control Placebo
Description: oral capsule
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tasimelteon Placebo
Description: oral capsule
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tasimelteon Placebo
Description: oral capsule
Study NCT06323655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: oral capsule
Study NCT04348760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rotation Diet
Description: Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
Study NCT03950531 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01698723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01698723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01345266 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inhalation Profiling
Description: All subects recieve Inhaltion Profiling there are no interventions.
Study NCT03252808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
Study NCT03252808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Study NCT03252808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Study NCT03252808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Study NCT01214382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Single dose sertraline 100 mg, tablet and solution
Study NCT02748395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Study NCT02748395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00489411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Given orally
Study NCT02748395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02416154 — intervention group
Intervention type: PROCEDURE
Intervention: Reproductive tract and blood sampling
Description: Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
Study NCT04371965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
Study NCT03593044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% concentration atropine drops
Description: One drop of 0.01% concentration atropine in each eye at night for seven days.
Study NCT00489411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT04136730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based
Description: Resistance exercise carried out unsupervised at home
Study NCT04337827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU).
Study NCT04337827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU.
Study NCT04337827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scans
Description: 2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
Study NCT04037826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475
Description: L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
Study NCT00890110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous renal cell vaccine based on DNP modified cells
Description: Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
Study NCT03320720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Treatment
Description: Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
Study NCT03320720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
Study NCT03772262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: goldenseal
Description: Oral 500 mg capsules
Study NCT03772262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral solution
Study NCT04037826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00802295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotrophins
Description: Administration of standard ovarian stimulation protocol
Study NCT00802295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dosis Gonadotrophin
Study NCT03772262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution